Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (121-130 of 151) with videos related to

Pageof 16
Sort By:
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology Oncology|September 11, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b TrialMaria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 16

Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
European Urology|August 27, 2019
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate CancerAlex P Hoyle, Adnan Ali, Nicholas D James, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
European Urology Oncology|September 11, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b TrialMaria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapyTomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2019
Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international databaseNicolas Delanoy, Anne-Claire Hardy-Bessard, Eleni Efstathiou, et al.
Pageof 16